reports
- ABGSC Media Research
- Derek Laliberté
- ABGSC Healthcare Research
- Sten Gustafsson
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; January 29, 2026 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, ...
Elekta AB: 1 director
A director at Elekta AB maiden bought 9,000 shares at 60.550SEK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 21, 2026 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 14,351 million in 2025. Net trade sale...
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) f...
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progress...
- ABGSC Healthcare Research
- Sten Gustafsson
Actic Group AB: 1 director
A director at Actic Group AB sold 77,400 shares at 36.020SEK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Genmab Partners with Anthropic to Accelerate Research and Development ...
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence Media ReleaseCOPENHAGEN, Denmark; January 07, 2026 Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody medicines to patients (Nasdaq: GMAB) announced today a partnership with Anthropic to advance and enhance the company’s research and development (R&D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities. Under the agreement, Genmab and Anthropic will de...
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; January 5, 2026 (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco at 3:45 PM PST / 6:45 PM EST on January 13, 2026, 12:45 AM CET on January 14, 2026. The live and archived webcast of the presentation will be available on Genmab’s website at . About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other ...
Genmab Portfolio Prioritization Update
Genmab Portfolio Prioritization Update Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio reviewDecision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and increasingly competitive landscapeThis decision does not impact Genmab’s full‑year 2025 financial guidance COPENHAGEN, Denmark; December 29, 2025 – (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s strategic focus on the most value‑creating opportuni...
L E Lundbergforetagen AB: 1 director
A director at L E Lundbergforetagen AB sold 60,000 shares at 500.785SEK and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Genmab Announces Completion of Tender Offer for Outstanding Common Sha...
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolioTransaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidia...
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting Media Release Event to be held virtually via live webcast and archived on Copenhagen, Denmark; December 11, 2025 – (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting today, December 11, 2025 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually and can be attended via live webcast. To register for the webcast, click . An archive of the webcast will be available on Genmab’s website. This meeting is not an official program of the ASH Annual Meeting. About Genmab Genmab i...
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting P...
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) Media ReleaseCOPENHAGEN, Denmark; December 8, 2025 Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for those unsuitable for chemotherapy Additional early data show promising efficacy of epcoritamab combination regimens in patients with RT Results underscore the potential...
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstra...
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clinically meaningful reduction in the risk of disease progression or death and overall response compared to R2 aloneEPKINLY + R2 was recently approved by the U.S. F...
Genmab Announces Data From Multiple Clinical Trials Showing Treatment ...
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial results show encouraging overall response and complete response rates for epcoritamab monotherapy in newly-diagnosed, elderly patients with DLB...
Genmab Announces Closing of Private Offering of Senior Secured Notes a...
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their previously announced offering of $1.5 billion of 6.250% senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of 7.250% senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). Genmab intends to use the net proceeds from this offe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.